MONTGOMERY, ambien hungover mornings cymbalta adderall Ala. Kowa Company, Ltd. 34 billion ($340 million) in Japan. The APR products and technologies are licensed to third parties for distribution and marketing activities.
.
News
(KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U. Food and Drug Administration (FDA) has approved Cambia, a diclofenac-based non-steroidal anti-inflammatory drug ("NSAID") combined with potassium bicarbonate, for the treatment of acute migraine with or without aura in adults. is a specialty pharmaceutical company focused primarily in the area of cardiology. R&D activities are carried out directly or under contract. and King Pharmaceuticals, Inc. King's wholly-owned subsidiary, Alpharma, Inc.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act")..
Home
Courses
Policies & Documents
Information
Links
